Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on October 8, 2024. The company, which utilizes its proprietary ARCUS® platform for developing in vivo gene editing therapies, will present during a fireside chat at 11:00 AM ET.
The presentation will be accessible via webcast, with registration available through a provided link. Investors can also view the presentation on Precision's website under the Investors section, Events & Presentations. An archived replay will be available for approximately 30 days after the event.
Precision BioSciences (Nasdaq: DTIL), un'azienda avanzata nel campo dell'editing genetico, ha annunciato la sua partecipazione alla 5ª Conferenza Virtuale Annuale sulle Epatiti Virali di H.C. Wainwright che si svolgerà il 8 ottobre 2024. L'azienda, che utilizza la sua piattaforma proprietaria ARCUS® per sviluppare terapie di editing genico in vivo, presenterà durante un'intervista informale alle 11:00 AM ET.
La presentazione sarà disponibile tramite webcast, con registrazione disponibile attraverso un link fornito. Gli investitori possono anche visualizzare la presentazione sul sito web di Precision nella sezione Investitori, Eventi e Presentazioni. Una registrazione archiviata sarà disponibile per circa 30 giorni dopo l'evento.
Precision BioSciences (Nasdaq: DTIL), una empresa avanzada de edición genética, ha anunciado su participación en la 5ª Conferencia Virtual Anual sobre Hepatitis Viral de H.C. Wainwright el 8 de octubre de 2024. La empresa, que utiliza su plataforma propietaria ARCUS® para desarrollar terapias de edición genética in vivo, presentará durante una charla informal a las 11:00 AM ET.
La presentación estará disponible a través de un webcast, con registro disponible a través de un enlace proporcionado. Los inversores también pueden ver la presentación en el sitio web de Precision en la sección de Inversores, Eventos y Presentaciones. Una repetición archivada estará disponible durante aproximadamente 30 días después del evento.
Precision BioSciences (Nasdaq: DTIL), 첨단 유전자 편집 회사가 H.C. Wainwright 제5회 연례 바이럴 간염 가상 회의에 참여한다고 발표했습니다. 이 회의는 2024년 10월 8일에 열릴 예정입니다. 이 회사는 ARCUS® 플랫폼을 사용하여 체내 유전자 편집 치료제를 개발하며, 오전 11:00 ET에 진행되는 대담 중 발표할 예정입니다.
발표는 웹캐스트를 통해 접근 가능하며, 제공된 링크를 통해 등록할 수 있습니다. 투자자들은 Precision 웹사이트의 투자자 섹션, 이벤트 및 발표에서 발표를 볼 수 있습니다. 아카이브된 재생은 이벤트 후 약 30일 동안 제공될 예정입니다.
Precision BioSciences (Nasdaq: DTIL), une entreprise avancée dans le domaine de l'édition génétique, a annoncé sa participation à la 5e Conférence Annuelle Virtuelle sur les Hépatites Virales de H.C. Wainwright qui se déroulera le 8 octobre 2024. L'entreprise, qui utilise sa plateforme propriétaire ARCUS® pour développer des thérapies d'édition génétique in vivo, présentera lors d'un entretien informel à 11h00 ET.
La présentation sera accessible via un webcast, avec inscription disponible par un lien fourni. Les investisseurs pourront également visionner la présentation sur le site Web de Precision dans la section Investisseurs, Événements et Présentations. Un replay archivé sera disponible pendant environ 30 jours après l'événement.
Precision BioSciences (Nasdaq: DTIL), ein fortschrittliches Unternehmen für Genbearbeitung, hat seine Teilnahme an der 5. virtuellen Jahrestagung zu Virushepatitis von H.C. Wainwright am 8. Oktober 2024 bekannt gegeben. Das Unternehmen, das seine proprietäre ARCUS®-Plattform für die Entwicklung von in vivo-Geneingrifftherapien nutzt, wird in einem Kamininterview um 11:00 Uhr ET präsentieren.
Die Präsentation wird über einen Webcast zugänglich sein, mit Registrierung über einen bereitgestellten Link. Anleger können die Präsentation auch auf der Website von Precision im Bereich Investoren, Veranstaltungen und Präsentationen ansehen. Ein Archiv wird ungefähr 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
Presentation Details:
Date: October 8, 2024
Time: 11:00AM ET
Format: Fireside Chat
Webcast Registration: Link
The presentation will be available on Precision’s website under the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay will be available for approximately 30 days following the event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003129609/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
Source: Precision BioSciences, Inc.
FAQ
When is Precision BioSciences (DTIL) presenting at the H.C. Wainwright Viral Hepatitis Conference?
What type of presentation will Precision BioSciences (DTIL) give at the conference?
How can investors access Precision BioSciences' (DTIL) presentation at the H.C. Wainwright conference?
What is the main focus of Precision BioSciences' (DTIL) gene editing technology?
